GLEN ALLEN, Va., July 18, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: CIGX) today announced plans for the production and sale of its new Anatabloc® face cream. The company anticipates a launch of the product during the third quarter of this year.
(Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO )
The Anatabloc® face cream is based upon the company’s prior work with anatabine and its anatabine citrate formulation. Anatabine is an alkaloid found in Solanaceous plants, including tomatoes, peppers, eggplants, and tobacco, and has properties that improve the appearance of the skin. Anatabine citrate has been under consideration for use in the face cream since the systemic and topical safety of this natural ingredient was established. After a year of product development, which included efforts to find suitable bases for the product, consultation with several eminent dermatologists, and evaluation of pilot formulations of the cream, the company has created an effective product with promising results for the skin.
Dr. Curtis Wright, Senior Vice President and Medical/Clinical Director of Star Scientific’s wholly owned subsidiary Rock Creek Pharmaceuticals Inc., stated, “We think that anatabine has been a helpful and useful nutritional supplement and it is very exciting that there is a completely unexpected new cream based on anatabine and anatabine citrate products. I have personally reviewed the pilot work, and the results of this new Anatabloc® face cream in improving the appearance of the skin in subjects have been impressive.”
It is anticipated that initially the Anatabloc® face cream will be available on-line through the company’s website www.anatabloc.com and in select dermatology practices. The Anatabloc® face cream is a natural extension of the work that the company has been involved with in connection with its Anatabloc® dietary supplement for anti-inflammatory support. Anatabloc® can be purchased in all GNC corporate stores and in select franchise stores, as well as online at www.anatabloc.com or www.gnc.com.
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism, as well as to reduce the harm associated with the use of tobacco at every level. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also has continued to pursue the development, implementation, and licensing of the technology behind its proprietary StarCured® tobacco curing process, which substantially prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable tobacco products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA.
Contact:
Talhia T. Tuck
Vice President, Communications and Investor Relations
Star Scientific, Inc.
(301) 654-8300
ttuck@starscientific.com
SOURCE Star Scientific, Inc.
